The first patient has been dosed in a first-in-human clinical trial evaluating HLD-0915 for metastatic castration-resistant ...

Naïve CD8 T cells can change into different types of effector and memory CD8 T cells when the immune system responds to ...

A Yale University study explores the newly defined post-vaccination syndrome (PVS), revealing alarming biological changes ...

Adverse physical functions were indicative of reduced survival and increased risk of immune effector cell–associated neurotoxicity syndrome (ICANS) in patients with non-Hodgkin lymphoma (NHL) ...

Mustang Bio, Inc. ("Mustang" or the "Company") (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs ...

DONGGUAN, China I February 28, 2025 I Fapon Biopharma, a biotech innovator in developing therapeutic antibodies and fusion proteins, is pleased to announce ...

Mustang expects to continue to rely on its academic partners and future contract manufacturing relationships to support clinical trials. As a result of the termination of its lease, the Company ...

The leading Cutaneous Squamous Cell Carcinoma Companies such as Incyte Corporation, Shanghai Henlius Biotech, Novartis, ...

NEW YORK, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss ...

Veloxis Pharmaceuticals, Inc. (Veloxis), a global specialty pharmaceutical company and an Asahi Kasei company, has announced ...

Medicenna Therapeutics (MDNA) announced the presentation of new clinical data from its ongoing ABILITY-1 study evaluating MDNA11 alone or in ...

Memorial Sloan Kettering Cancer Center researchers have found RNA neoantigen vaccines that generate long-lived, functional ...